Most patients receiving a GLP-1 receptor agonist (RA) and a biologic continue co-therapy for over a year with few treatment-related adverse events.

Patient advocate Howard Chang’s visit to Boehringer Ingelheim’s biopharmaceutical facility revealed both how biologic ...

INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, ...

As more drugs go subcutaneous, Phillips Medisize's director of Front-End Innovation, Tony Bedford, believes that high-dose biologics will become a prevalent choice for drugmakers.

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

In this video interview, Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at the Northwestern ...

Tumour necrosis factor (TNF) inhibitors are more likely discontinued due to ineffectiveness in patients aged 16-24 years than in those aged 45-54 years. However, patients aged ≥ 75 years have an ...

A 46-year-old man presents for his first dermatology consultation for worsening symptoms of plaque psoriasis and recent-onset joint pain. He reports “painful aching” and swelling of his finger joints, ...

The idea that mental disorders are caused by a biological mechanism is linked with prolonged use of antidepressants and ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Download Brochure With its high efficiency and simplified ...

Rystiggo (rozanolixizumab) is a brand-name subcutaneous infusion that’s prescribed for myasthenia gravis. Rystiggo has interactions with some other drugs. Examples include immunoglobulins and ...